0001127602-14-035924.txt : 20141223 0001127602-14-035924.hdr.sgml : 20141223 20141223161331 ACCESSION NUMBER: 0001127602-14-035924 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141219 FILED AS OF DATE: 20141223 DATE AS OF CHANGE: 20141223 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 BUSINESS PHONE: 2054444600 MAIL ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Babu Yarlagadda S CENTRAL INDEX KEY: 0001452635 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 141307045 MAIL ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2014-12-19 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001452635 Babu Yarlagadda S 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 Senior VP - Drug Discovery Emp. Stock Option (Right to Buy) 5.45 2014-12-19 4 A 0 17000 0 A 2014-12-19 2023-08-08 Common Stock 17000 17000 D On December 19, 2014, the U.S. Food and Drug Administration (FDA) approved RAPIVAB (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on December 19, 2014. /s/ Alane P. Barnes, by power of attorney 2014-12-23